Metabolic Phenotyping Predicts Gemcitabine and Cisplatin Chemosensitivity in Patients With Cholangiocarcinoma.

Front Public Health · 2022 · PMC8866176 · PMID 35223723

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Additionally, high expressions of CD133 and CD44V8-10 tended to be associated with the non-response pattern to cisplatin, while the high expressions of ALDH1A1, EpCAM, CD133, CD44V6, and CD44V8-10 showed a trend to be positively correlated with the non-response pattern to gemcitabine significance which was not reached ( Table 3 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.